RE: True25 Apr 2017 11:15
FDA approval of their generic Advair is due May 10th - the last application for such a drug (Mylan) was dismissed by the FDA a few weeks ago. I think on the back of this their is some uncertainty about the immediate future for VEC's share price.
N+1 Singer have downgraded to sell and an article on the Financial Times site suggests 105p is possible if the product is rejected and are looking at it as a 50-50 call.
In my own opinion I feel the chances are higher (in favour of approval) given that the FDA have been invited to do numerous pre-approval checks on the product and the fact it is already licensed in Europe. After the FDA rejected Mylan's product they also gave a damning assessment of one of their India plants in which they stated :
"Until you correct all violations completely and we confirm your compliance with CGMP, FDA may withhold approval of any new applications or supplements listing your firm as a drug manufacturer,"
If it is rejected, from what is in their recent accounts, I am still confident this share will have it's day.
GL